- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07615374
Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
A Prospective Registry Study of Laparoscopic-endoscopic Cooperative Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Jilin
-
Ch’ang-ch’un, Jilin, China, 130021
- The First Hospital of Jilin University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
1. Preoperative assessment indicating that the tumor was confined to the mucosa or submucosa, consistent with the diagnosis of early gastric cancer.
2. Patients who required additional surgical intervention following initial endoscopic submucosal dissection (ESD) based on postoperative pathological evaluation.
3. Patients and their families fully understood the procedure, requested dual-endoscope assisted sentinel lymph node navigation surgery, agreed to participate in this clinical study, and signed the informed consent form.
Exclusion Criteria:
1. Preoperative assessment indicating suspected lymph node or distant metastasis.
2. History of complex abdominal surgery rendering laparoscopic treatment infeasible.
3. Participation in another clinical trial within 4 weeks prior to enrollment or currently participating in another trial.
4. History of severe psychiatric disorders. 5. Pregnant or lactating women. 6. Uncontrolled infection prior to surgery. 7. Presence of other malignancies or comorbidities that may significantly affect survival.
8. Any other conditions deemed by the investigators as unsuitable for participation, or refusal by the patient or family to enroll.
9. Cardiopulmonary, hepatic, and renal functions were unsufficient to tolerate the surgery.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Sentinel Lymph Node Navigation Surgery
Laparoscopic-endoscopic cooperative surgery (LECS) Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
|
After preoperative assessment and confirmation of eligibility, patients received general anesthesia with endotracheal intubation.
Indocyanine green (ICG) was injected submucosally around the lesion in four quadrants to trace the sentinel lymph node (SLN) basin.
Laparoscopic marking of the SLN basin was performed.
Endoscopy assisted laparoscopy in marking the primary lesion border (ensuring a margin of >0.5 cm).
Laparoscopic sentinel lymph node dissection was performed, followed by endoscopic/laparoscopic full-thickness resection of the lesion.
Gastric wall defects were closed laparoscopically.
SLNs were harvested and sent for intraoperative frozen section pathology.
If positive, a standard radical gastrectomy was performed; if negative, an abdominal drainage tube was placed to complete the procedure.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of perioperative complications.
Zeitfenster: One month after surgery
|
Postoperative complications comprised hemorrhage, obstruction, gastrointestinal motility disorders, and fistulas.
The overall complication rate was calculated as the number of patients with complications divided by the total number of patients in the cohort.
|
One month after surgery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of retrieved lymph nodes.
Zeitfenster: One week after the surgery.
|
The number of lymph nodes retrieved from all resected specimens.
|
One week after the surgery.
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Postoperative hospital stay (days).
Zeitfenster: One month after the surgery.
|
Time from surgery to discharge was recorded in days.
|
One month after the surgery.
|
|
Time to first resumption of liquid diet
Zeitfenster: One month after surgery.
|
Time to first resumption of liquid diet was recorded in days.
|
One month after surgery.
|
|
R0 resection rate
Zeitfenster: One month after surgery.
|
The R0 resection rate was defined as the proportion of patients with histopathologically confirmed complete resection and negative margins among all enrolled patients.
|
One month after surgery.
|
|
Hospitalization costs.
Zeitfenster: One month after surgery.
|
Total hospitalization costs were calculated in Chinese Yuan (CNY).
|
One month after surgery.
|
|
Number of patients requiring further therapy
Zeitfenster: Three month after surgery.
|
Number of patients requiring further therapy (e.g., standard radical gastrectomy or chemotherapy).
|
Three month after surgery.
|
|
Cytological examination results of peritoneal lavage fluid.
Zeitfenster: One week after surgery.
|
Cytological examination of the irrigation fluid from the surgical field was performed postoperatively.
A finding of tumor cells was considered positive.
|
One week after surgery.
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 130019
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Früher Magenkrebs
-
Western University, CanadaNoch keine RekrutierungeTRE (Early Time Restricted Eating) mit BCAA | eTRE (Early Time Restricted Eating)Kanada
-
Institut fuer FrauengesundheitLilly Deutschland GmbH Germany; AGO-B Breast Study GroupRekrutierungHR+/HER2- Early BrustkrebsDeutschland
-
Institut fuer FrauengesundheitLilly Deutschland GmbH GermanyNoch keine RekrutierungHR+/HER2- Early BrustkrebsDeutschland
-
Western University, CanadaUnbekannteTRE (Early Time Restricted Eating) | lTRE (Late Time Restricted Eating)Kanada
-
Western University, CanadaNoch keine RekrutierungeTRE (Early Time Restricted Eating) | eTRE mit BISC (kurzes intensives Treppensteigen)Kanada
-
Xijing HospitalAbgeschlossen
-
Novartis PharmaceuticalsRekrutierungHR+/HER2- Early BrustkrebsSaudi-Arabien
-
Azienda Ospedaliera Specializzata in Gastroenterologia...MedtronicNoch keine RekrutierungGAVE - Gastric Antral Vascular Ectasie
-
Assiut UniversityNoch keine RekrutierungGAVE - Gastric Antral Vascular Ectasie
-
H. Lee Moffitt Cancer Center and Research InstituteColumbia University; University Hospitals Cleveland Medical Center; Geisinger... und andere MitarbeiterZurückgezogenBlutung | GAVE - Gastric Antral Vascular Ectasie | Blutender MagenVereinigte Staaten